Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for macular oedema following central retinal vein occlusion
ACTRN12611000300976Phase 2Recruiting
- Sponsor
- Royal Adelaide Hospital
- Start
- Feb 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab in central retinal vein occlusion (CRVO) (2 arms), sponsored by Royal Adelaide Hospital. Primary endpoint: Best corrected visual acuity. Started Feb 2009; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on ACTRN12611000300976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000300976.